A carregar...
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope(®) (biosimilar rhGH) was approved by the European Medicines Agency in 2006, with approval granted...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439985/ https://ncbi.nlm.nih.gov/pubmed/28553080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130909 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|